Review AOD-9604 dosage protocol claims about daily amounts, divided doses, cycles, and reconstitution, alongside the limits of route-specific human evidence.
There is no validated human subcutaneous AOD-9604 dosage protocol. AOD-9604 is not FDA-approved, and online daily amounts, divided injections, and cycle lengths should not be presented as research-established treatment guidance.
The details below describe laboratory and self-reported research use only. They are not medical advice.
What Is AOD 9604?
AOD-9604 is a modified fragment of human growth hormone: hGH residues 177-191 with an added N-terminal tyrosine, making a 16-amino-acid peptide. It is often called HGH fragment 176-191, although it is not the unchanged native sequence.
The oral obesity trial summarized in FDA's 2024 review enrolled 536 participants and randomized 502 to placebo or 0.25, 0.5, or 1 mg daily for 24 weeks. It did not show a statistically significant benefit on the primary weight-loss endpoint at 12 weeks. These oral results do not establish an effective subcutaneous dose.
AOD 9604 is a research chemical that is not approved by the FDA for treating obesity or any other medical condition.
What Would Establish a Dosage Protocol?
An effective protocol requires human evidence for the same route and formulation, with measured outcomes and safety follow-up. A commonly repeated forum amount does not meet that standard.
| Protocol claim | Evidence needed | Current limitation in the reviewed evidence |
|---|---|---|
| Starting amount | Human subcutaneous dose-finding and tolerability data | No validated starting amount established |
| Standard daily amount | A reproducible clinical dose-response relationship | Oral trial arms cannot establish this |
| Split or higher amounts | A direct exposure and outcome comparison | No validated advantage from the reviewed data |
In its 2024 review, FDA did not identify human subcutaneous exposure data or human pharmacokinetic studies for AOD-9604. Oral and intravenous findings cannot establish the absorption, half-life, effectiveness, or safety of an internet-sourced subcutaneous product.
Converting a 5 mg Vial Into Example Volumes
The aod-9604 5mg dosage question often mixes concentration arithmetic with a human dosing recommendation. The conversions below use a hypothetical 300 mcg amount solely to demonstrate the calculation; they do not establish a dose, a diluent choice, or a schedule.
- 5 mg vial + 1 mL water = 5,000 mcg per mL, so 300 mcg is about 0.06 mL.
- 5 mg vial + 2 mL water = 2,500 mcg per mL, so 300 mcg is about 0.12 mL.
- Insulin syringes marked in units make these small volumes easier to draw.
When and How Often to Take AOD 9604
For how often do you take aod 9604, a once-daily oral trial does not establish once-daily or split injections. No validated human subcutaneous interval was established by the 2024 review.
There is no established clinical advantage to fasting or pre-training administration in the reviewed injection evidence. Claims based on insulin changes or fat oxidation require direct testing.
- Morning: no validated advantage over other times from the reviewed human injection data.
- Before exercise: a physiological theory is not proof of improved AOD-9604 outcomes.
- Before bed: normal growth-hormone secretion does not establish a schedule for this modified fragment.
A claimed short half-life cannot justify a timing protocol without human subcutaneous pharmacokinetics. The review did not identify human pharmacokinetic studies.
AOD 9604 Cycle Length and Stacking
No evidence-based aod 9604 cycle length or washout interval is established by the reviewed human injection evidence. Published oral study durations should not be converted into injection cycles.
Discussions of aod 9604 vs mots-c concern different compounds, not validated stacking guidance. A plausible difference in mechanism does not establish a safe or effective combination.
| Feature | AOD-9604 | MOTS-c |
|---|---|---|
| Research origin | Modified growth-hormone fragment | Mitochondrial-derived peptide |
| Validated injection protocol | Not established in the reviewed AOD-9604 human evidence | Community protocols are not validated treatment |
| Human subcutaneous half-life | Not established in the 2024 FDA review | Requires separate evidence |
| Research focus | Fat metabolism | Metabolic signaling |
| US approval | Not FDA-approved | Not FDA-approved |
Reconstitution and Handling
Preparation must use a validated procedure for the specific formulation, concentration, and intended research application. Bacteriostatic water is not automatically compatible with every peptide product.
Cloudy, thick, or stringy samples, sometimes described as aod-9604 gelling up, should not be used. Appearance alone cannot establish whether the cause is formulation, degradation, contamination, or another factor.
- Follow the formulation-specific storage procedure rather than a universal freezer or refrigerator rule.
- Do not infer the mixed product's shelf life from a generic multi-week window or the diluent label.
- Avoid handling changes that are not supported by the preparation procedure.
- Clean handling does not replace sterility, identity, or stability testing.
Safety, Side Effects, and Legal Status
AOD-9604 has no FDA-approved human drug product. A research-use listing does not establish pharmaceutical identity, peptide content, sterility, or lawful human treatment.
Reported human safety findings must be tied to the oral or intravenous routes studied. They do not establish that a subcutaneous regimen causes only mild effects or has predictable long-term risk.
Anyone considering AOD 9604 should discuss it with a licensed healthcare professional first, especially if they take other medications or have a medical condition. This article is informational and is not a substitute for medical advice. Related research also covers AOD 9604 Dosage: Chart, Units, and Dosing Schedule.
RELATED PEPTIDE TOPICpeptide dosing guideFrequently Asked Questions
How much AOD 9604 do people typically use per day?
Amounts repeated in community protocols are not validated human dosing guidance. The reviewed human evidence did not establish a subcutaneous starting amount, daily total, escalation plan, or split schedule. AOD-9604 has no FDA-approved human drug product.
How long can you run an AOD 9604 cycle?
No evidence-based injection cycle length or washout period is established by the reviewed human data. An oral trial's duration does not validate an injection cycle, and taking a planned break does not by itself establish safety.
Does AOD 9604 need to be injected on an empty stomach?
No food-free interval for human subcutaneous use is established by the reviewed evidence. Morning fasting, pre-training timing, and split amounts should not be presented as validated clinical guidance.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.